New drug comment - escitalopram

Comment on: Antifungal therapy: drug-drug interactions at your fingertips.

The Information Age has revolutionized the ability of healthcare professionals (HCPs) to oversee a substantial body of clinically relevant information literally at one's fingertips. In the field of clinical pharmacology, this may be particularly useful for managing drug-drug interactions (DDIs). A thorough understanding of the underlying mechanisms of DDIs allows the HCP to predict such interac...

Workplace drug abuse policy: A comment

McGuire and Ruhm (1993) develop an interesting and policy-relevant model of workplace drug abuse policy. They examine workers’ choice to undergo treatment (rehabilitation) for substance abuse and firms’ choice of drug-testing policies, concluding that ‘labor market incentives will generally lead to too little treatment and too much testing’. Drug addicts are assumed to have a ‘high’ probability...

New Dimension in Drug Addiction Therapy

Breaking Gridlock in Health Policy?; Comment on “A New Synthesis”

Pierre-Gerlier Forest has put forward the case that we are on the brink of a revolution in health policy that will be the result of the interplay of five factors. I would not challenge any of them but would emphasize the need to address socio-economic health inequalities, which have the potential to become a major cost driver in a time of growing economic inequality. To Dr. Forest’s list, I wou...

[Uveal effusion induced by escitalopram].

CASE REPORT A 73 year-old woman with depression treated with escitalopram developed acute secondary angle closure glaucoma related to uveal effusion after duplicating the drug dose 3 days before. She evolved favorably once the antidepressant treatment was suspended and a new treatment with topical hypotensive therapy and oral prednisone was used. DISCUSSION The uveal effusion syndrome associa...